Diarmid has over 28 years’ investment experience in both the public and private equity markets. As a seed investor, he co-founded Wejo and has served as a Non-Executive Director since its inception in January 2014. Together with Richard Barlow, he has developed the investment strategy and helped to raise the significant amount of capital invested in Wejo.
After beginning his career as an equity analyst at S.G Warburg, he became a founding member of the CROCI® Valuation Group at Deutsche Bank. This group developed a systematic proprietary equity valuation methodology based on the Cash Returns on Capital Invested of companies. The methodology became the platform for investable indices with over $10bn in assets under management at Deutsche and is still employed today.
Since 2007, he has led a number of private equity investments into fast growing companies across a variety of sectors, including Wejo. In 2014, Diarmid became a seed investor in Grind - a fast-growing, specialist coffee brand - and served as Chairman from 2014 through August 2021. In addition, alongside the chief architects of CROCI®, he is a Co-Founding Shareholder of ValuAnalysis, an independent investment boutique focusing on public equities and specialising in valuation.
Diarmid serves as a Stakeholder Governor of University College London Hospitals (one of the largest National Health Service Trusts in the UK), where he chairs the Nomination, Appointments & Remuneration Committee. He is also a Trustee and Vice Chair of The National Brain Appeal, a charity which supports the work of The National Hospital for Neurology & Neurosurgery, a University College London Hospital.
Diarmid holds a BA cum laude from Princeton University and an MBA from INSEAD.